{
  "id": "fda_guidance_chunk_0688",
  "title": "Introduction - Part 688",
  "text": "12.5 – 13.5 10.5 – 12.4 8.5 – 10.4 < 8.5 Hemoglobin (Male) change from baseline value – gm/dL Any decrease – 1.5 1.6 – 2.0 2.1 – 5.0 > 5.0 WBC Increase - cell/mm3 10,800 – 15,000 15,001 – 20,000 20,001 – 25, 000 > 25,000 WBC Decrease - cell/mm3 2,500 – 3,500 1,500 – 2,499 1,000 – 1,499 < 1,000 Lymphocytes Decrease - cell/mm3 750 – 1,000 500 – 749 250 – 499 < 250 Neutrophils Decrease - cell/mm3 1,500 – 2,000 1,000 – 1,499 500 – 999 < 500 Eosinophils - cell/mm3 650 – 1500 1501 - 5000 > 5000 Hypereosinophilic Platelets Decreased - cell/mm3 125,000 – 140,000 100,000 – 124,000 25,000 – 99,000 < 25,000 PT – increase by factor (prothrombin time) 1.0 – 1.10 x ULN** 1.11 – 1.20 x ULN 1.21 – 1.25 x ULN > 1.25 ULN PTT – increase by factor (partial thromboplastin time) 1.0 – 1.2 x ULN 1.21 – 1.4 x ULN 1.41 – 1.5 x ULN > 1.5 x ULN Fibrinogen increase - mg/dL 400 – 500 501 – 600 > 600 -- Fibrinogen decrease - mg/dL 150 – 200 125 – 149 100 – 124 < 100 or associated with gross bleeding or disseminated intravascular coagulation (DIC) * The laboratory values provided in the tables serve as guidelines and are dependent upon institutional normal parameters. Institutional normal reference ranges should be provided to demonstrate that they are appropriate. ** “ULN” is the upper limit of the normal range. Urine * Mild (Grade 1) Moderate (Grade 2) Severe (Grade 3) Potentially Life Threatening (Grade 4) Protein Trace 1+ 2+ Hospitalization or dialysis Glucose Trace 1+ 2+ Hospitalization for hyperglycemia Blood (microscopic) – red blood cells per high power field (rbc/hpf) 1 - 10 11 – 50 > 50 and/or gross blood Hospitalization or packed red blood cells (PRBC) transfusion * The laboratory values provided in the tables serve as guidelines and are dependent upon institutional normal parameters. Institutional normal reference ranges should be provided to demonstrate that they are appropriate. Contains Nonbinding Recommendations IV. REFERENCES 1. National Cancer Institute Common Toxicity Criteria, April 30, 1999. (http://ctep.cancer.gov/reporting/CTC-3.html) 2. Division of AIDS Table for Grading Severity of Adult Adverse Experiences; August 1992. (http://rcc.tech-res-intl.com/tox_tables.htm) 3. The Brighton Collaboration. Finalized Case Definitions and Guidelines. (http://brightoncollaboration.org/internet/en/index/definition___guidelines.html) 4. HIV",
  "source": "FDA_clinical_trial_guidance.txt",
  "section_heading": "Introduction",
  "start_pos": 923328,
  "end_pos": 924864,
  "tokens": 512,
  "tags": [
    "safety",
    "statistical"
  ],
  "jurisdiction": "US",
  "document_type": "fda_guidance",
  "guidance_section": "general_guidance",
  "regulatory_weight": "guidance",
  "created_at": "2025-10-23T02:25:44.731Z"
}